California-based True North Therapeutics has appointed Pamela Wapnick as its new chief financial officer.
Wapnick joins the rare diseases clinical stage biopharmaceutical company from Amgen, where she most recently served as vice president of finance.
Prior to this, Wapnick had corporate finance responsibility for Amgen’s global research and development activities, and has served as vice president and treasurer of Amgen.
She brings over 25 years of international business and finance experience to True North, including senior financial management positions at Delphi Corporation, Federal Mogul Corporation and General Motors Corporation.
Nancy Stagliano, chief executive officer of True North, said: “I am pleased to announce Pam’s appointment to the position of chief financial officer as a member of our management team.
“Her breadth of experience in corporate finance and treasury within the biotechnology industry, including nearly 10 years and Amgen, will serve us well as we continue to advance True North’s pipeline of novel product candidates.”